Disease · MONDO_0015277
medullary thyroid gland carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. medullary thyroid gland carcinoma. Diseases, record MONDO_0015277. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015277
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
C cell carcinoma, MTC, carcinoma of parafollicular cell, carcinoma, C-cell, malignant, medullary carcinoma, medullary carcinoma of the thyroid, medullary carcinoma of the thyroid gland, medullary carcinoma of thyroid, medullary carcinoma of thyroid gland, medullary thyroid cancer, medullary thyroid carcinoma, parafollicular cell carcinoma, thyroid gland medullary cancer, thyroid gland medullary carcinoma, thyroid gland neuroendocrine carcinoma, thyroid medullary carcinoma
- Open Targets
- Highest stage of its drugs
- Approval, for 4 of its 52 drugs, from ClinicalTrials.gov, DailyMed and PMDA
- Open Targets
Drugs52
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VANDETANIB | CHEMBL24828 | Small molecule | Approval | DailyMed and PMDA | 15 | 13 | 13 | Drugs and targets |
| CABOZANTINIB | CHEMBL2105717 | Small molecule | Approval | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| PRALSETINIB | CHEMBL4582651 | Small molecule | Approval | ClinicalTrials.gov and DailyMed | 5 | 4 | 4 | Drugs and targets |
| SELPERCATINIB | CHEMBL4559134 | Small molecule | Approval | DailyMed | 5 | 4 | 4 | Drugs and targets |
| CATEQUENTINIB | CHEMBL4303201 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Protein | Phase 2 | ClinicalTrials.gov | 4 | 4 | 2 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| LENVATINIB | CHEMBL1289601 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 52
See all 52 drugsTargets131
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 15 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 12 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2321 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 10 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 9 | Stem cell growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| RET | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | 8 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor | Approval | https://conductscience.org/library/genes/5979 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 6 | Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 5 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 4 | Serine/threonine-protein kinase B-raf inhibitor | Phase 2 | https://conductscience.org/library/genes/673 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 4 | Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2260 | Drugs and targets |
1 to 10 of 131
See all 131 targetsTrials64
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Phase 1/2 | 590 | 2025-05-31 | RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer, RET-altered Solid Tumors, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Thyroid Diseases, Thyroid Neoplasm, Thyroid Cancer, Papillary, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasm, Head and Neck Neoplasms, Adenocarcinoma, Papillary, Adenocarcinoma, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Colonic Neoplasms, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Disease, Colonic Diseases, Intestinal Disease | PRALSETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00410761 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | Phase 3 | 331 | 2012-03-26 | Thyroid Cancer | VANDETANIB | Its record names the disease | ClinicalTrials.gov |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | Phase 3 | 330 | 2014-09-09 | Thyroid Cancer | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | Phase 3 | 291 | 2024-06-13 | Medullary Thyroid Cancer | CABOZANTINIB, SELPERCATINIB, VANDETANIB | Its record names the disease | ClinicalTrials.gov |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer | Phase 4 | 247 | 2025-09-02 | Medullary Thyroid Cancer | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01298323 | Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment | Phase 3 | 205 | 2014-11-24 | Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer | VANDETANIB | Its record names the disease | ClinicalTrials.gov |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1/2 | 200 | 2020-10-19 | Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors | ROVALPITUZUMAB TESIRINE | Its record names the disease | ClinicalTrials.gov |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | Phase 2 | 152 | 2020-02-26 | Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma | PAZOPANIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00784303 | Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology | Phase 2 | 117 | 2019-08-01 | Thyroid Cancer | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01496313 | To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | Phase 4 | 81 | 2015-11-27 | Thyroid Cancer | VANDETANIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 64
See all 64 trialsComparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vandetanib 300 mg vs Placebo: Biochemical Response Carcinoembryonic Antigen (CEA) | 119 of 231 | 2 of 100 | 331 | NCT00410761 | Trial comparisons |
| Vandetanib 300 mg vs Placebo: Biochemical Response Calcitonin (CTN) | 160 of 231 | 3 of 100 | 331 | NCT00410761 | Trial comparisons |
| Vandetanib 300 mg vs Placebo: Disease Control Rate (DCR) | 200 of 231 | 71 of 100 | 331 | NCT00410761 | Trial comparisons |
| Vandetanib 300 mg vs Placebo: Objective Response Rate (ORR) | 104 of 231 | 13 of 100 | 331 | NCT00410761 | Trial comparisons |
| XL184 (Cabozantinib) vs Placebo: serious adverse events | 90 of 214 | 25 of 109 | 323 | NCT00704730 | Trial comparisons |
| Selpercatinib - Treatment A (TRT A) vs Cabozantinib or Vandetanib - Treatment B (TRT B): deaths from any cause | 8 of 193 | 10 of 97 | 290 | NCT04211337 | Trial comparisons |
| Selpercatinib - Treatment A (TRT A) vs Cabozantinib or Vandetanib - Treatment B (TRT B): serious adverse events | 43 of 193 | 27 of 97 | 290 | NCT04211337 | Trial comparisons |
| Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg: deaths from any cause | 59 of 123 | 51 of 124 | 247 | NCT01896479 | Trial comparisons |
| Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg: serious adverse events | 55 of 123 | 62 of 124 | 247 | NCT01896479 | Trial comparisons |
| Vandetanib 300mg vs Vandetanib 300mg + Outreach Program: serious adverse events | 30 of 103 | 27 of 102 | 205 | NCT01298323 | Trial comparisons |
1 to 10 of 30
See all 30 comparisons in its trialsPapers from its trials63
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015277
GET https://conductscience.org/api/diseases/v1/MONDO_0015277/drugs?page=2